2012
Inhibition of CD44 Gene Expression in Human Skin Models, Using Self-Delivery Short Interfering RNA Administered by Dissolvable Microneedle Arrays
Lara MF, González-González E, Speaker TJ, Hickerson RP, Leake D, Milstone LM, Contag CH, Kaspar RL. Inhibition of CD44 Gene Expression in Human Skin Models, Using Self-Delivery Short Interfering RNA Administered by Dissolvable Microneedle Arrays. Human Gene Therapy 2012, 23: 816-823. PMID: 22480249, PMCID: PMC3413896, DOI: 10.1089/hum.2011.211.Peer-Reviewed Original ResearchConceptsTransgenic mouse modelInhibition of CD44CD44-specific antibodiesCD44 mRNA levelsDissolvable microneedle arraysGene expressionMouse modelXenograft modelSkin disordersCD44 gene expressionHuman skin modelTarget cellsMRNA levelsHuman skin equivalentsKeratinocyte membraneTreatmentInhibitionStratum corneumTarget gene expressionSiRNASkin equivalentsEpidermal equivalentsMicroneedle arraysSkin modelExpression
2010
Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials
Hickerson RP, Leachman SA, Pho LN, Gonzalez-Gonzalez E, Smith FJ, McLean WH, Contag CH, Leake D, Milstone LM, Kaspar RL. Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials. Journal Of Investigative Dermatology 2010, 131: 1029-1036. PMID: 21191405, DOI: 10.1038/jid.2010.372.Peer-Reviewed Original ResearchConceptsClinical trialsPachyonychia congenitaEnd pointPhase 1b clinical trialClinical end pointsRare skin disorderMolecular end pointsTypes of trialsImmune surveillancePatient-derived keratinocytesSkin disordersSustained inhibitionTreatment resultsRNAi-based therapeuticsRNA interferenceMRNA levelsTrialsTotal RNAHuman skinKeratinocyte culturesMRNAAmplifiable mRNATherapeuticsInhibitorsInhibition